chrisvoncsefalvay/vaers-outcomes huggingface dataset:
started around 9am on 03/05/2021 with lower back muscle pain which I found odd, as the day has progressed a headache started and has kept on increasing on intensity, around 2pm I got sleepy and slept for about 30 minutes, the headache continue but now muscle pain discomfort is now down my knees and I started feeling body aches, I drove to pick up my child from school at 4pm and noticed confusion and irritability, once I got home took my temp and was 97.9 a few minutes later 98.2 now is 98.4, I called vaers at 8008227967 and the woman was not helpful at all in fact she was annoyed by the call, once I insist she hear what I have to say then she sounded nervous and wanted to get a statement but I decided to call moderna instead at 8666633762 and they listened and took my statement and said that more likely I will get a phone call, the side effects got so intense that I forgot I had a follow appointment with my primary care for a physical. I called them and they had me marked down for no show but once I explained they set up another follow up appointment.
Right deltoid hot to touch, firm with softness noted to about elbow, swollen to elbow, complaints pain today, no pain yesterday. No fever. Mom noted symptoms this AM at 9:00, advised to call/visit pediatrician.
This rreport was received from manufacturer research and was assigned manufacturer report number HQ5709310DEC2002. This report concerns a 15 month old female pt who on 12/3/02 was vaccinated with a dose of MMR II. On 12/5/02 the pt experienced an afebrile grand mal convulsion. The outcome was reported as unknown. Afebrile grand mal convulsion was considered to be an other important medical event (OMIC). This was originally reported by a nurse practitioner. Additional info has been requested. Follow up info received on 1/13/02, from a healthcare professional provided product lot numbers, an additional vaccine that was administered, immunization administration sites, and event outcome. A nurse practitioner reported that a 15 month old female received her third dose of Prevnar on 12/3/02. Concomitant vaccines included Hib-Titer and MMR II. On 11/13/02, the thid received FluShield. Medical history included a febrile convulsion at 4 months of age. At the time of immunization, she was experiencing mild cold symptoms. On 12/5/02, the child develped an afebrile grand mall seizure and was taken to the ER. She was not hospitalized. On 12/6/02, the child was seen in the office and was "playing and seemed fine." The reporter indicated the child recovered. The healthcare professional planned to schedule an EEG and a computerized axial tomogram. This event was considered medically important (OMIC). The follow up received on 1/15/03 states on an unspecified date, electroencephalogram and a computerized axial tomogram were performed, the results wree negative. Follow up info was received from a nurse practitioner indicating that the pt had her first dose of Prevnar in Jan 2002 after which she had a grand mal seizure. The pt did not experience any seizure after the second dose of Prevnar vaccine was given in Sep 2002. The pt had since had another grand mal seizure on 1/3/03. The pt was not hospitalized and a CAT scan and electroencephalography were normal. The pt was evaluated by a neurologist on 1/16/03. The afebrile grand mal convulsion and grand mal seizure were considered to be other important medical events (OMIC). No further info is expected.
Tremors in both of her hands; This is a spontaneous case reported by other health professional to Agency (reference number: SEQ19-05023) and initially retrieved on 17-Oct-2019, concerning a 31-year-old, female patient.  The patient had no relevant medical history.  The patient's concomitant medications were not provided.  On 17-Oct-2019, the patient was administered Flucelvax QIV [Influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5ml, route of administration: intramuscular, anatomical location: left deltoid, batch number: 259808, expiration date: 31-May-2020] for protection against seasonal influenza.  On the same day, about an hour after vaccination, the patient experienced tremors in both of her hands. Nurse stated that she was worried because the patient had no history of this occurring.   The outcome of the event was recovered after a couple of hours. As reported, during this time, patient's vitals were normal. Patient had no additional issues after tremors resolved.   The reporter assessed the case as non-serious. Causality assessment was not provided.  Follow up received from other health professional on 05-Nov-2019: Stop date and outcome of the event were updated. The narrative was amended accordingly.  Company comment: The patient developed tremor one the same day, about an hour after administration of suspect product, Flucelvax QIV. Chronology is plausible. The patient had no relevant medical history or concomitant medications. Reportedly, the event resolved after couple of hours. With information currently available, causal role of the suspect product is assessed as unlikely related.; Sender's Comments: The patient developed tremor one the same day, about an hour after administration of suspect product, Flucelvax QIV. Chronology is plausible. The patient had no relevant medical history or concomitant medications. Reportedly, the event resolved after couple of hours. With information currently available, causal role of the suspect product is assessed as unlikely related.
This is a spontaneous report from a contactable consumer reporting for herself. A 18-year-old female patient received second dose of TRUMENBA, via an unspecified route of administration, on 12MAY2015, at single dose. Relevant medical history was not reported. Concomitant medications included ADDRALL at 5 mg daily and PROZAC at 20 mg daily. The patient experienced chills, she was shaking a lot, she got shoot headaches and she felt very bad as she got a sudden reaction on 12MAY2015. Outcome of the reported events was not recovered at the time of this report.  Follow-up (01JUL2015): Follow-up attempts completed. No further information expected.
Headache, sweats, sore joints, pain & numbness down injected arm, nausea, lethargy
Diffuse hives starting 9 days after dose, continuing for 10 days (seen in office on day 10, not resolved).
the patient was so sick, thought that the patent was having a heart attack; Initial information regarding this unsolicited valid non-serious social media case received from a consumer (patient) and transmitted to Sanofi on 13-Dec-2020.  This case involves a patient of an unknown demography who was so sick, thought that the patent was having a heart attack (illness), while the patient received INFLUENZA VACCINE.  Relevant medical history, past medical treatment, vaccination details, concomitant medications and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and expiry date not reported) via an unknown route in unknown administration site for prophylactic vaccine.  On an unknown date, it was reported that the patient was so sick, thought that the patent was having a heart attack (illness) unknown latency following the administration of INFLUENZA VACCINE.  No laboratories details reported.   It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome was unknown for the reported event.  There would be no information available on batch number for this case.
redness at the injection site; redness at the injection site from the injection site all the way down to her elbow; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included sleep apnea and memory impairment. Previously administered products included Shingrix (received 1st dose on an unknown date). Concurrent medical conditions included osteopenia and asthma.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site erythema and erythema. On an unknown date, the outcome of the injection site erythema and erythema were recovered/resolved.   It was unknown if the reporter considered the injection site erythema and erythema to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient reported that, she started Nucala about a year ago from the date of reporting.  Before starting Nucala, the patient received both doses of Shingrix.  After receiving 2nd dose of Shingrix, the patient experienced redness at the injection site from the injection site all the way down to her elbow.  The patient also said that, she had missed her doses of Nucala during the month of February.  She might miss March's dose if she did not get it quickly shipped to her.  The patient had missed her doses because she forgot to call and request it to Nucala. The patient was experiencing some congestion as a result of not taking Nucala, because her symptoms were coming back. The patient also stated that, she had experienced swelling of her legs. She had spoken to her physician about it and they could not figure out what was causing it. This started happening recently and while on Nucala. For the tolerance of Nucala dose, refer linked case US2021AMR060167. The reporter did not consent to follow-up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR060167:same patient
Patient developed low fever and a severe rash all over body with target lesions 10 days after vaccination and taken to ER where he was given steroids.  He was seen at the clinic 5 days later where he was found with the same rash (mom said was a bit better).  No fever.  Diagnosed with erythema multiforme.  Mom stopped steriods and child was prescribed antihistamine/Pepcid combination.  Called today (1 week later) and mom referred rash is fading away and child is well.
Administered an immunization for patients age 18 and up, to a 17-year old. No ADRs reported upon follow up with patient and patient mother.
Patient had previously received one dose of the covid 19 monovalent vaccine, and had not yet received a second dose of the covid 19 monovalent vaccine. Covid 19 bivalent vaccine administered to patient on 9/29. According to CDC recommendations, patient should have received a second dose of the covid 19 monovalent vaccine before receiving a dose of the bivalent vaccine.   No symptoms or reactions to vaccine noted.
Two hours after received vaccine child became inconsolable and resisting weight bearing for approximately two hours. Improved after Tylenol. Completely resolved by next morning. afebrile, slight redness at site of DTaP.
FLANK PAIN; BACK PAIN; CHILLS; INJECTION SITE SORENESS; FEVER; MUSCLE ACHES AND SORENESS; HEADACHE; This spontaneous report received from a patient concerned a 31 year old male. The patient's weight was 97.4 pounds, and height was 61 inches. The patient's concurrent conditions included abstains from alcohol, and non smoker, and other pre-existing medical conditions included patient had no known allergies. the patient did not have any drug abuse/ illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 041A21A, expiry: 21-JUN-2021) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 08-APR-2021, the subject experienced flank pain. On 08-APR-2021, the subject experienced back pain. On 08-APR-2021, the subject experienced chills. On 08-APR-2021, the subject experienced injection site soreness. On 08-APR-2021, the subject experienced fever. On 08-APR-2021, the subject experienced muscle aches and soreness. On 08-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from chills, and fever on 09-APR-2021, was recovering from injection site soreness, muscle aches and soreness, back pain, and flank pain, and the outcome of headache was not reported. This report was non-serious.
first dose /in September 2019/ has not received the second dose yet; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 59-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in September 2019, Batch number 77PL3, expiry date 18th April 2021.).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional case details were reported as follows: The age at vaccination was not applicable for this report. Till the time of reporting, the patient had not received the 2nd dose, which led to incomplete course of vaccination. The VAERS details were reported for 1st dose. The case had been linked with US2020042797, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020042797:Same reporter
Second COVID-19 booster given too early. First booster 5/12/2022.
I saw my cardiologist on April 17th, and he has sent me to another cardiologist for a flutter. I am seeing the other cardiologist this Monday coming up. They plan on doing a cardiac ablation.
pt stated that she had SOB, muscle aches, diarrhea, nauseated for about 2 days.  Pt is now feeling better and has not contacted PCP.
tested positive for Covid 19 4/09/2021 symptoms were mild and able to treat at home. symptoms included loss of taste/ smell, severe sinus congestion/ headache, fatigue, and muscle weakness
Per the client's stepmother: The client went to work following the injection and began to feel nauseous and tired. The client called her father to come pick her up, and threw up before he arrived. The client began to go in and out of consciousness in the car, so her father took her to the emergency room. There she was treated with IV fluids and diagnosed with an anxiety attack. Per the stepmother the client returned home that evening and is tired but otherwise feeling ok.
TEMP 99.1F , BODY ACHES, HOT FLASHES, CHILLS
Bad headache daily Difficulty sleeping nightly. Tossing and turning most of the night.
Pt. received Td, IPV, HPV, Hep A and the flu vaccine. After 10 seconds pt. started to feel dizzy and fainted. This episode lasted for a few seconds and pt. woke up. Was examined by provider. Did not eat anything before.
Fever, extreme headache, extreme joint pain, extreme body ache, chills, sweating, swollen glands, sore throat, loss of appetite, restlessness
Pt received vaccine on 11/6/2012, went to Dr for swelling and itching in her arm. Dr called pharmacy and report the reaction and prescribed antibiotic.
ankles swollen & painful x 2 wks worse in AM; edema & pain migrate from joint to joint;
Fever; Headaches; Body Shaking; Insomnia; This is a spontaneous report from a contactable consumer (Patient). A 24-year-old male patient received first dose bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, formulation: solution for injection, Lot Number: EW0217) via an unspecified route of administration in arm left on 10Jun2021 13:45 (age at the time of the vaccination 24 year) as dose 1, single for COVID-19 immunization. Medical history included COVID. No COVID tested post vaccination. Concomitant medications included gabapentin, clonidine and bupropion hydrochloride (WELLBUTRIN). On 10Jun2021 23:00, the patient experienced fever, headaches, body shaking and insomnia. No treatment received for the adverse events. On an unspecified date in 2021, the events recovered.   Follow-up attempts are completed. No further information is expected.
This spontaneous report was received from a Registered nurse regarding 18 year old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 21 -JUN-2017, the patient was vaccinated with improperly stored dose of GARDASIL 9 (lot# N004798 with expiration date: 31-OCT-2019) (dosing details and route of administration was not reported) for prophylaxis (product storage error). No adverse effects were reported. The storage temperature was 47 degrees Fahrenheit to 77 degrees Fahrenheit (49F) and time frame was 14 hours. There was no previous temperature excursion. Digital data logger was involved. No product quality complaint was involved. This is one of the several reports from the same reporter. Sender's Comments: US-009507513-1804USA005153.
Since vaccination/past few months, has been developing worsening proteinuria. Underwent allograft biopisy which demonstrated severe transplant glomerulopathy.   Patient presented to transplant center on 5/21 and blood pressure was found to be severely elevated x 1 month. Patient was referred to the emergency department and presented on 5/21 with blood pressure in the 190s, lower extremity edema, intermittent chest pain for the past few months, anemia, and AKI. Labs in the ED were significant for hemoglobin of 6.7, hematocrit of 22.7, BUN of 83, PLTs of 83 and serum creatinine of 3.7 (baseline 1.7). UA significant for proteinuria. Patient was transfused with 1 unit PRBC in ED and admitted for further evaluation.  Nephrology consulted 5/21. Working diagnosis for patient's proteinuria, thrombocytopenia, and AKI was atypical hemolytic uremic syndrome (aHUS). Lab results significant on 5/23 included HgB of 6.3 despite 1 unit of PRBC, PLTs worsened to 62, slight improvement in SCr to 3.3. Multiple repeat PRBC administered over the next few days without improvement in HgB. Patient was started on Soliris weekly infusion 5/25 for treatment of presumed aHUS. 5/26 Adam TS-13 level returned normal, indicating low likelihood for TTP. Stabilization and improvement in labs occurred throughout the next several days, with 5/29 labs HgB of 8.0 and PLTs of 79. 5/29 SCr remained elevated at 3.4. Patient was discharged on 5/29 with plans for outpatient nephology follow-up and aHUS genetic testing. At 8/13 outpatient follow-up CBC returned normal, but SCr remains elevated at 3.1. Genetic testing panel for aHUS returned negative on 8/26. Etiology of aHUS now thought to be due to COVID-19 vaccination.
This is a spontaneous report from a contactable healthcare professional reporting similar events for 4 patients. This is  the first of 4 reports. A patient of unknown age and gender received intramuscular PREVNAR13 Lot number: J80525, Expiration date: APR2016, NDC number: 0005-1971-02, single dose, on an unknown date. On unknown date the patient's injection site was red, hot and swollen, and had skin discoloration that was very large, also experienced fever and injection site pain. The outcome of events was unknown. Follow-up (03MAR2015): This follow-up report is being submitted to amend previously reported information: to amend the reporter information as the reporter was calling on behalf of a doctor.
DVT Left calf. Started as pain in the left calf on morning after vaccination. Seen by PCP 1 week later with persistent pain. Diagnosed by ultrasound. Confirmed by hematologist and started on Xarelto same day.
Pain, swelling, warm to touch at site.  Area below site 3cm.  Fever.  Tx: cephalexin 500mg QID x7 days.
Within an hour lost all taste. Within 3 hours fever and chills. By next day muscle aches and lethargy. As of today's date still have no taste. The fever, chills, muscle aches lasted until March 3rd. Since the 3rd I have had random fevers that are gone within a few hours. I'm still exhausted all the time.
Nausea; Headache; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nausea), HEADACHE (Headache) and FATIGUE (Fatigue) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Apr-2021, the patient experienced NAUSEA (Nausea), HEADACHE (Headache) and FATIGUE (Fatigue). At the time of the report, NAUSEA (Nausea), HEADACHE (Headache) and FATIGUE (Fatigue) outcome was unknown.            No concomitant medications were reported No treatment medications were reported.   This case was linked to MOD-2021-378227, MOD-2021-378238 (Patient Link).
Blurred vision, headache, stomach ache and fatigue 24 hours after receiving vaccine -> GARDASIL #2.
I noticed numbness in my right cheek and upper lip that lasted several hours.  The symptoms recur almost daily, usually in the afternoon.  Today the symptoms caused numbness in my upper gums and upper teeth on the right side.  I read that the H1N1 which I had on January 9th can cause Guillain-Barre syndrome.
Skin reaction, Medication error, Nonspecific reaction, Skin lesion. Eczema, Adverse event. This case was reported by the mother of a consumer and described the occurrence of skin reactions (dermatological reaction) in a 9 year old male subject who was vaccinated with influenza virus vaccine (flu vaccine, Glaxosmithkline) for prophylaxis. A physician or other health care professional has not verified this report. Concurrent medications included Multivitamins. On 22-October- 2007, in the afternoon, the subject received unspecified dose of Flu vaccine, the subject developed what the mother referred to as a dermatological reaction (skin reaction). A systemic reaction. He developed lesions (described as nummular) on his hands, wrists, arms and the back of the ankles. It had been called eczema as well as some other unidentifiable term (spngia). The condition has lasted for about 8 months as of the time of reporting and the mother did report that there was only one lesion left. The condition responds to steroids, but when they are stopped the symptoms return. The subject has also been treated with mupirocin (clay park labs) and this worsened the lesions. The child has reportedly seen several dermatologists as well as allergist. Hwas tested for everything and it all comes back negative. the first flu vaccine the subject ever recieved was by aventis and he ended up with over 300 lesions. at the time of reporting the outcome of the events were unspecified. This was also considered to be a medication error as Glaxosmithkline flu vaccine is not indicated for use in pediatric subjects. These events occurred in this subject in 2006 following vaccianition with a Glaxosmithkline flu vaccine. Refer to case number A0739B53A for details surrounding the first report.
"Moderna COVID19 Vaccine "; patient reported she was feeling flushed/hot. Vital signs were taken and patient monitored for over 30 minutes. BP and Heart Rate readings approximately every 10 minutes: BP 142/105, HR 110; BP 139/101, HR 110;  BP 132/83, HR 104; 124/94, HR 102; 98 % pulse oximeter readings during episode. Patient's mother works at the facility as well, stayed with patient and decided to leave with patient to go home.  Mother returned inside facility and stated daughter was vomiting outside. Dr. advise mother to take daughter to ER.
At approximately 1719 the patient in question alerted the nurse that she was having facial swelling, difficulty swallowing and problems breathing. At 1723 patient administered her own EpiPen into her right lateral thigh, almost immediately patient reported ease with breathing and swallowing. Nurse noted facial swelling had resolved. At 1728 vitals were taken: BP 130/86, O2 sat 100%, pulse 90 temp 99.4F. EMS called at 1724 and arrived at 1734, patient was able to ambulate to ambulance without assistance.
pt recv vax 10OCT95 & devel redness @ the inj site;no tx necessary;pt recovered;
Headache, shortness of breath, face swelling, body hives,  upper torso - neck, shoulder,  arm and shoulder blade pain.